see below. mmwr on influenza control. i felt proud to know that one of the influenza strains covered by the vaccine is from massachusetts. we finally made it.
you can click on the link to read the whole article. just a couple of changes:
–Boston added!
–several new formulations, including quadrivalent, egg-free (for ages 18-49 only). we only have the trivalent at the health center at this point
there was info a couple of years ago suggesting deceasing efficacy of the live attenuated vaccine (LAIV) vs inactivated as people reach the ripe old age of around 35-40. (i don’t have that reference). not mentioned in mmwr. there was an article comparing vaccines (see DOI:10.1111/j.1750-2659.2010.00183.x) which suggested that the live vaccine may be more effective as a priming vaccine and the TIV more effective in boosting pre-existing immunity. which could explain the age difference (if it is real). i personally stopped using the LAIV in patients over late 30’s because of the data from a few years ago, but since not mentioned in MMWR, probably it is okay to use it.
geoff
From: Centers for Disease Control & Prevention [mailto:cdc@service.govdelivery.com]
Sent: Thursday, September 19, 2013 12:19 PM
To: Modest, Geoffrey A.,M.D.
Subject: MMWR Vol. 62 / No. RR-7
| Having trouble viewing this email? View it as a Web page.
|
If you have trouble reading this e-mail, please click here.
|
|
|
|
|
Recommendations and Reports
Volume 62, No. RR-7
September 20, 2013
|
|
|
|
|
|
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization
Practices — United States,
2013–2014
|
|
|
|
|
|
This report updates the 2012 recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza. Routine annual influenza vaccination is recommended for all persons aged ≥6 months. For the 2013–14 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013–14 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)–like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012–like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B/Brisbane/60/2008–like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This information is intended for vaccination providers, immunization program personnel, and public
health personnel.
|
|
|
full text
|
|
|
|
| |
|
Department of Health and Human Services
Centers for Disease Control and Prevention
|
|
|
|
| This email was sent to gmodest@partners.org using GovDelivery, on behalf of: Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta, GA 30333 · 1-800-CDC-INFO (800-232-4636) |
|
|
(Visited 2 times, 1 visits today)